Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
In clinical practice, patients with <i>anaplastic lymphoma kinase (ALK)</i>-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of <i&g...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/13/11/371 |
| _version_ | 1797548636142305280 |
|---|---|
| author | Maximilian J. Hochmair Hannah Fabikan Oliver Illini Christoph Weinlinger Ulrike Setinek Dagmar Krenbek Helmut Prosch Markus Rauter Michael Schumacher Ewald Wöll Romana Wass Elmar Brehm Gudrun Absenger Tatjana Bundalo Peter Errhalt Matthias Urban Arschang Valipour |
| author_facet | Maximilian J. Hochmair Hannah Fabikan Oliver Illini Christoph Weinlinger Ulrike Setinek Dagmar Krenbek Helmut Prosch Markus Rauter Michael Schumacher Ewald Wöll Romana Wass Elmar Brehm Gudrun Absenger Tatjana Bundalo Peter Errhalt Matthias Urban Arschang Valipour |
| author_sort | Maximilian J. Hochmair |
| collection | DOAJ |
| description | In clinical practice, patients with <i>anaplastic lymphoma kinase (ALK)</i>-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of <i>ALK</i> resistance mutations and thus offers potential benefit in later lines, although real-world data are lacking. This multicenter study retrospectively investigated later-line, real-world use of lorlatinib in patients with advanced <i>ALK</i>- or <i>ROS1</i>-positive lung cancer. Fifty-one patients registered in a compassionate use program in Austria, who received second- or later-line lorlatinib between January 2016 and May 2020, were included in this retrospective real-world data analysis. Median follow-up was 25.3 months. Median time of lorlatinib treatment was 4.4 months for <i>ALK</i>-positive and 12.2 months for <i>ROS</i>-positive patients. <i>ALK</i>-positive patients showed a response rate of 43.2%, while 85.7% percent of the <i>ROS1</i>-positive patients were considered responders. Median overall survival from lorlatinib initiation was 10.2 and 20.0 months for the <i>ALK</i>- and <i>ROS1</i>-positive groups, respectively. In the <i>ALK</i>-positive group, lorlatinib proved efficacy after both brigatinib and alectinib. Lorlatinib treatment was well tolerated. Later-line lorlatinib treatment can induce sustained responses in patients with advanced <i>ALK</i>- and <i>ROS1</i>-positive lung cancer. |
| first_indexed | 2024-03-10T15:02:27Z |
| format | Article |
| id | doaj.art-c5a19e6cd3264f17ba16255cddad1e6e |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T15:02:27Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-c5a19e6cd3264f17ba16255cddad1e6e2023-11-20T20:06:02ZengMDPI AGPharmaceuticals1424-82472020-11-01131137110.3390/ph13110371Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter AnalysisMaximilian J. Hochmair0Hannah Fabikan1Oliver Illini2Christoph Weinlinger3Ulrike Setinek4Dagmar Krenbek5Helmut Prosch6Markus Rauter7Michael Schumacher8Ewald Wöll9Romana Wass10Elmar Brehm11Gudrun Absenger12Tatjana Bundalo13Peter Errhalt14Matthias Urban15Arschang Valipour16Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, AustriaDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, AustriaDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, AustriaDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, AustriaInstitute of Pathology and Clinical Microbiology, Wilhelminenspital, Montleartstrasse 37, 1160 Vienna, AustriaInstitute of Pathology and Clinical Microbiology, Wilhelminenspital, Montleartstrasse 37, 1160 Vienna, AustriaDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Währingergürtel 18–22, 1090 Vienna, AustriaClinic of Pneumology, Klinikum Klagenfurt am Wörthersee, Feschnigstrasse 11, 9020 Klagenfurt am Wörthersee, AustriaOrdensklinikum Linz Elisabethinen, Fadingerstrasse 1, 4020 Linz, AustriaSt. Vinzenz Krankenhaus Betriebs GmbH, Klostergasse 10, 6511 Zams, AustriaDepartment of Pneumology, Johannes Kepler University Linz, Krankenhausstrasse 26–30/Med Campus IV, 4020 Linz, AustriaDepartment of Pneumology, Johannes Kepler University Linz, Krankenhausstrasse 26–30/Med Campus IV, 4020 Linz, AustriaDepartment of Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, AustriaLandesklinikum Hochegg, Hocheggerstrasse 88, 2840 Hochegg, AustriaClinical Department of Pneumology, University Hospital Krems, Mitterweg 10, 3500 Krems, AustriaDepartment of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, AustriaDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, AustriaIn clinical practice, patients with <i>anaplastic lymphoma kinase (ALK)</i>-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of <i>ALK</i> resistance mutations and thus offers potential benefit in later lines, although real-world data are lacking. This multicenter study retrospectively investigated later-line, real-world use of lorlatinib in patients with advanced <i>ALK</i>- or <i>ROS1</i>-positive lung cancer. Fifty-one patients registered in a compassionate use program in Austria, who received second- or later-line lorlatinib between January 2016 and May 2020, were included in this retrospective real-world data analysis. Median follow-up was 25.3 months. Median time of lorlatinib treatment was 4.4 months for <i>ALK</i>-positive and 12.2 months for <i>ROS</i>-positive patients. <i>ALK</i>-positive patients showed a response rate of 43.2%, while 85.7% percent of the <i>ROS1</i>-positive patients were considered responders. Median overall survival from lorlatinib initiation was 10.2 and 20.0 months for the <i>ALK</i>- and <i>ROS1</i>-positive groups, respectively. In the <i>ALK</i>-positive group, lorlatinib proved efficacy after both brigatinib and alectinib. Lorlatinib treatment was well tolerated. Later-line lorlatinib treatment can induce sustained responses in patients with advanced <i>ALK</i>- and <i>ROS1</i>-positive lung cancer.https://www.mdpi.com/1424-8247/13/11/371<i>ALK</i>-positive disease<i>ROS1</i>-positive diseaseALK tyrosine kinase inhibitor treatmentsequential treatmentlorlatinib |
| spellingShingle | Maximilian J. Hochmair Hannah Fabikan Oliver Illini Christoph Weinlinger Ulrike Setinek Dagmar Krenbek Helmut Prosch Markus Rauter Michael Schumacher Ewald Wöll Romana Wass Elmar Brehm Gudrun Absenger Tatjana Bundalo Peter Errhalt Matthias Urban Arschang Valipour Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis Pharmaceuticals <i>ALK</i>-positive disease <i>ROS1</i>-positive disease ALK tyrosine kinase inhibitor treatment sequential treatment lorlatinib |
| title | Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
| title_full | Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
| title_fullStr | Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
| title_full_unstemmed | Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
| title_short | Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
| title_sort | later line treatment with lorlatinib in i alk i and i ros1 i rearrangement positive nsclc a retrospective multicenter analysis |
| topic | <i>ALK</i>-positive disease <i>ROS1</i>-positive disease ALK tyrosine kinase inhibitor treatment sequential treatment lorlatinib |
| url | https://www.mdpi.com/1424-8247/13/11/371 |
| work_keys_str_mv | AT maximilianjhochmair laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT hannahfabikan laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT oliverillini laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT christophweinlinger laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT ulrikesetinek laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT dagmarkrenbek laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT helmutprosch laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT markusrauter laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT michaelschumacher laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT ewaldwoll laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT romanawass laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT elmarbrehm laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT gudrunabsenger laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT tatjanabundalo laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT petererrhalt laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT matthiasurban laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis AT arschangvalipour laterlinetreatmentwithlorlatinibinialkiandiros1irearrangementpositivensclcaretrospectivemulticenteranalysis |